title: [Brain functional state and cytoprotective potential in model of acute cerebral hypoxia (experimental research)].
abstract: The functional state of the brain and the potential of pharmacologic cytoprotection after an acute cerebral hypoxia were studied. The experiment involved 186 adult male rats. The rats in experimental groups underwent acute thromboembolism of the right carotid artery. The functional state of the brain and the efficacy and safety of the Cytoflavin complex cytoprotective drug treatment had been analyzed over the 10 days following the thromboembolism. A neurological examination was accomplished daily, the serum levels of NSE, GFAP, S100beta and brain cytolysate levels of NSE were measured on the 1st, 3rd, 10th day. The NSE brain cytolysate level went up on the 1st day and the NSE serum level was up on the 3rd day following the thromboembolism, which may have indicated an acute delayed alteration of neurons and an increase of the blood-brain barrier permeability on the 3rd day after the thromboemboIism. Neuroglial biomarkers went up on the 1st (GFAP), 3rd and 10th (S100beta) day, which indicated an acute delayed alteration and/or activation of glial cells. Therefore, the applied experimental model promotes acute delayed alteration of neurons and neuroglia with a possible activation of the latter. The Cytoflavin proved to have a cytoprotective effect on neurons and to diminish the alteration and/or activation of glial cells over the observed period after the acute thromboembolism of the carotid artery.
authors.forename: N V
authors.initials: NV
authors.lastname: Tsygan
authors.forename: A P
authors.initials: AP
authors.lastname: Trashkov
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000503:physiopathology; D001921:Brain / Q000378:metabolism* / Q000503:physiopathology; D002341:Carotid Artery Thrombosis / Q000150:complications; D004338:Drug Combinations; D005486:Flavin Mononucleotide / Q000009:adverse effects / Q000627:therapeutic use*; D002534:Hypoxia, Brain / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D007290:Inosine Diphosphate / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009419:Nerve Tissue Proteins / Q000097:blood / Q000378:metabolism; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009536:Niacinamide / Q000009:adverse effects / Q000627:therapeutic use*; D010751:Phosphopyruvate Hydratase / Q000097:blood / Q000378:metabolism; D051381:Rats; D064568:S100 Calcium Binding Protein beta Subunit / Q000097:blood / Q000378:metabolism; D013386:Succinates / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D064568:S100 Calcium Binding Protein beta Subunit; C579158:S100b protein, rat; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate; D010751:Phosphopyruvate Hydratase